Pfizer inches up on launching new medication for migraine treatment
Pfizer is currently trading at Rs. 5064.00, up by 5.75 points or 0.11% from its previous closing of Rs. 5058.25 on the BSE.
The scrip opened at Rs. 5055.00 and has touched a high and low of Rs. 5069.00 and Rs. 5049.55 respectively. So far 33 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 5987.65 on 16-Jun-2025 and a 52 week low of Rs. 3742.90 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 5329.05 and Rs. 4980.15 respectively. The current market cap of the company is Rs. 23166.65 crore.
The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 19.70% and 16.37% respectively.
Pfizer has launched a new medication for migraine treatment. The company has introduced Rimegepant ODT in India for adults with a previous insufficient response to triptan, the usual drugs for treating migraine.
The new medication delivers rapid and sustained pain relief lasting up to 48 hours post-treatment, while not associated with the risk of medication overuse headaches. Rimegepant will be available in a 75 mg orally disintegrating tablet (ODT) form, designed for convenient administration without the need for water.
Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
.jpg)
